Collagen Peptides and Cellular Aging

The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease). Main questions it aims to answer are: Does six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health? Researchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers. Participants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation/redox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.

NCT Number	NCT07456449
Lead Sponsor	University of Vienna Collaborators: Collagen Research Institute
Conditions	Longevity, Healthy Aging, Biological Ageing
Enrollment	125 participants
Start Date	2026-04-22
Primary Completion	2028-02 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-05-05